Resource Hub

How the piggyBac^® Transposon Sheds Light on Breast Cancer Drug Resistance

A new study has harnessed the power of the piggyBac transposon gene editing system to unravel key resistance mechanisms and propose a novel therapeutic strategy for breast cancer.

The MCF-7 Breast Cancer Model: A Definitive Guide

The Hera Biolabs Guide to the MCF-7 Breast Cancer Model - history, ongoing applications, and its future relevance to oncology studies.

Advantages of Utilizing the SRG rat for Investigating Tumor Metastasis

A Fred Hutch research team employed SRG rats as a model organism to improve the detection of dissemination events. Through this approach, they identified a significant increase in the abundance of circulating tumor cells (CTCs).

The SRG OncoRat for Precision Cancer Medicine

How Outsourcing to an Animal Model Provider Saves Resources for Disease Researchers

Researchers' best practices for sourcing animal models and a look at advantages of using an animal model provider like Hera BioLabs with on-site vivaria and in-house breeding programs.

Addressing the limitations of chemotherapeutic drug delivery with engineered protein polymers

The standard care of treatment for many types of cancer and infectious diseases around the world is currently chemotherapy. However, chemotherapies are widely known to be linked to severe toxicity and resistance that develop mostly due to non-specificity, leading to overall disease progression.

OncoRat SRG – Outperforming The Mouse For Xenografts

Data indicating that the OncoRat® is more effective in xenograft studies compared to leading mouse models.

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

A case study showing that preclinical anticacancer studies can be vastly improved by using rats for xenografts.

SRG OncoRat , A SCID Model Ideal For Human Xenografts

A case study showing that preclinical anticacancer studies can be vastly improved by using rats for xenografts.

Frequently Asked Questions about the SRG™ Rat

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

OncoRat® SRGTM Outperforming the mouse for xenografts

View Our Webinar On The OncoRat For Xenografts And PDX

Hera’s talk at Scientist.com on using the SRG rat for the 3Rs

A Rag2/Il2rg double-knockout rat supports engraftment of human immune system for immunotherapy-based cancer efficacy studies

The SRG™ rat: A novel SCID rat for humanization studies

A Novel Immunodeficient Rat for Modeling Human Cancer

Novel immunodeficient rat models capable of supporting the growth of human tumor xenografts

Novel immunodeficient rat models offers a unique platform for drug efficacy studies in human tumor xenografts

Frequently Asked Questions about the SRG^™ Rat

OncoRat SRG – Outperforming The Mouse For Xenografts

Data indicating that the OncoRat® is more effective in xenograft studies compared to leading mouse models.

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

Hera BioLabs Offers In Vivo Bioluminescence Imaging For Pre-clinical Oncology

In vivo bioluminescent imaging in the SRGTM OncoRat® provides an ideal platform for de-risking your pipeline and developing life-saving pharmacotherapies.

SRG™ Rat (OncoRat^®) Enables Precision Medicine-Based Cancer Studies

Review of data showing high efficiency tumor take rates, growth kinetics, and successful precision medicine with difficult cell lines and PDXs

Cell Line Development

Hera Biolabs's Cas-CLOVER gene editing platform is ideal for CLD. It is easier to use than CRISPR with flexible and clear commercial terms. Send your CLD project to us to accelerate it and unburden your team.

Acute Myeloid Leukemia MOLM13 And Optimus

The US FDA recently released Project Optimus, a guideline impacting clinical pipelines for acute myeloid leukemia therapy. Read our blog for more information.

Hera BioLabs Announces Exclusive Global License with Charles River

Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, has announced a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera’s SRG rat (OncoRat®). The SRG rat is the first highly immunocompromised rat model, validated for xenograft studies in oncology and infectious disease research applications. 

Rapid Creation of Bioluminescent Cell Lines for Orthotopic and Metastatic Rodent Oncology Studies

In vivo bioluminescent imaging in the SRGTM OncoRat® provides an ideal platform for de-risking your pipeline and developing life-saving pharmacotherapies.

The SRG OncoRat for Precision Cancer Medicine

In Vivo Targeting Of Mutant KRAS Using Human Cancer Xenografts In The Immunodeficient SRG OncoRat®

Mutant human KRAS cell lines as xenografts are highly compatible with our SRG OncoRat animal research model

Hera’s Poster For American Association for Cancer Research (AACR) Annual Meeting 2021

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Maulhardt et al

Orally -Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Ponnusamy and Narayana et al

A 2019 Clinical Cancer Research Paper Review: Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

A case study showing that preclinical anticacancer studies can be vastly improved by using rats for xenografts.

HeraBioLabs | Ramesh Narayanan

HeraBioLabs | Goutham Narla

HeraBioLabs | Fallon Noto

Overcoming translational barriers by using the SRG Rat: case studies with the OncoRat®

The OncoRat – Three experts describe their experience

Fine Needle Aspirate Serial Tumor Sampling Services To Boost Your Xenograft Study Capabilities

Hera has full coverage on licensed technologies and is the first toxicology CRO focused on providing better predictability and sensitivity through genome editing technologies.

Validation Of The SRG Rat For Human Tumor Studies Published In PLOS ONE

Hera has full coverage on licensed technologies and is the first toxicology CRO focused on providing better predictability and sensitivity through genome editing technologies.

OncoRat® Featured In Clinical Cancer Research For Prostate Cancer Studies

Hera piloted VCaP xenografts, validated/assessed engraftment efficacy, and delivered rat xenograft models for both parental VCaP and MDVR.

The OncoRat® Is The Ideal Host For Patient-Derived Xenografts Of Ovarian Cancer Cells

Advances in cytotoxic, platinum-based chemotherapeutics combined with tumor resection surgery allows approximately 80% of these patients to achieve remission.

H358 NSCLC Xenografts In Humanized Rats: The Ideal In Vivo Model For Studying KRAS Mutations

Improved in vivo xenograft models using H358 may be valuable for preclinical studies examining KRAS-targeting agents or drug combinations.

Hera Biolabs Announces Molecular Cancer Therapeutics Publication On Immunodeficient Rats For Oncology Research

Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts."

Breakthroughs In Gene Editing Allow For The Creation Of Superior Preclinical Oncology Models

Hera Biolabs has used its proprietary gene editing technologies to develop ideal rat models for use in pre-clinical oncology research by oncology CROs.

The OncoRat®: Hosting Valuable Tumor Xenograft Models That Are Difficult Or Impossible To Study Using In Vitro Or Mouse Models

Xenograft models are an imperative preclinical model for understanding the role of specific oncogenic drivers, tumor suppressor losses, and homogenous cancer cells.

Patient Derived Xenograft Studies From Wider Varieties Of Patient Sub-Populations Promise Improved Clinical Trial Selection And Design

Around 85% of preclinical drugs entering clinical trials in oncology never make it past Phase 1 because they fail to demonstrate sufficient efficacy due to testing in unselected patient populations. Many of these failed agents are targeted therapies, meaning that they target specific oncogenic driver mutations.

OncoRat® PDX Models Highlighted In Drug Discovery News (DDN) Special Report On Cancer: Aiming For Avatars

While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the lack of important components, such as the influence of surrounding tissues and potential cell-to-cell interactions, when studying cancer progression, treatment responses and outcomes.

Using Patient Derived Xenografts To Improve Therapeutic Cancer Treatments

An understanding of human tumors has created a solid foundation for the creation of new anti-cancer treatments (many of which involve antineoplastic compounds).

Humanized Immune-System SRG Rats™ & Mice For Immuno-Oncology

Hera is now providing pre-implanted huPBMC-SRG rats as well as immuno-oncology studies in hu-PBMC-SRG rats, NSG mice and NOG mice.

Patient Derived Xenografts Possess Significant Advantages In The Study Of Urological Tumors

For researchers to model this complexity ongoing studies involving PDX murine models continuously show advantages when compared to the conventional CDX mice.

PDX Models of Lung Cancer Closely Mimic Characteristics Of Patient Primary Tumors

High throughput screening strategy, using larger PDX models, may be helpful in identifying broader responses to novel therapeutics in a pre-clinical setting.

Orthotopic vs. Subcutaneous Xenograft Models of Human Cancer

Orthotopic xenograft models seem to more closely mimic the tumor micro-environment and metastases as observed in human prostate cancer patients according to Journal of Cellular Biochemistry.

Humanized Mouse Xenograft Models: The Best Of Both Worlds

Immunized mice allowed for researchers to examine cancer xenograft growth in the context of a human-like immune system and resulting tumor microenvironment.

Xenograft Rat Models Give Hope To New Therapeutic Treatments For Leukemia

There is significant preclinical rational for clinical investigation of pharmacologic DOT1L inhibitors for DNMT3A-mutant leukemia (AML).

Advancements In Stem Cell-Based Therapies For Malignant Brain Tumors

MSCs, particularly human adipose-derived mesenchymal stem cells (hAMSCs), have great potential as brain tumor-targeting carriers of drug therapies.

New Transgenic Rat Models Offer Superior Representation Of Human Cancers

Utilizing embryonic injection of CRISPR, rodent models with spontaneous gene mutations can be created on most strains, leading to faster transgenic model creation timelines.

Could Xenograft Rats Be The Future of Leukemia Research?

In-vivo imaging techniques will be able to monitor and evaluate the efficacy of preclinical therapies with hopes of a cure for leukemia and other cancers.